YS Biopharma Co Ltd

LakeShore Biopharma Co., Ltd. is a biopharmaceutical enterprise dedicated to the discovery, development, manufacturing, and commercialization of vaccines and therapeutic biologics. These solutions are primarily aimed at combating infectious diseases and various forms of cancer. Central to its operations is the company's proprietary PIKA immunomodulating technology platform. Its product pipeline showcases significant developments, including the PIKA rabies vaccine, a PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. LakeShore Biopharma maintains a global operational footprint, with activities spanning China, the United States, Singapore, the United Arab Emirates, and the Philippines. Established in 2002, the company is headquartered in Beijing, China. It formally adopted the name LakeShore Biopharma Co., Ltd. in May 2024, having previously operated as YS Biopharma Co., Ltd.